Suda Pharmaceuticals LtdのEPS 1株当たり利益
Suda Pharmaceuticals LtdのEPS 1株当たり利益 は何ですか。
Suda Pharmaceuticals LtdのEPS 1株当たり利益 は-0.02です。
EPS 1株当たり利益 の定義は何ですか。
1株当たり利益（EPS) は、当社の1株当たり利益です。それは株式の希釈を考慮に入れ、 過去12ヶ月間にカウントされます。
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
ASXのセクタHealth CareにおけるEPS 1株当たり利益 の企業と比べるSuda Pharmaceuticals Ltd
Suda Pharmaceuticals Ltdは何をしますか。
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Suda Pharmaceuticals Ltdと類似のeps 1株当たり利益
- Fountainhall Capital CorpのEPS 1株当たり利益 は-0.02です。
- Hong Kong Television NetworkのEPS 1株当たり利益 は-0.02です。
- China SandiのEPS 1株当たり利益 は-0.02です。
- BExcellentのEPS 1株当たり利益 は-0.02です。
- Gitennes Exploration IncのEPS 1株当たり利益 は-0.02です。
- Horizon GoldのEPS 1株当たり利益 は-0.02です。
- Suda Pharmaceuticals LtdのEPS 1株当たり利益 は-0.02です。
- CollaborateのEPS 1株当たり利益 は-0.02です。
- Kelso TechnologiesのEPS 1株当たり利益 は-0.02です。
- Shen YouのEPS 1株当たり利益 は-0.02です。
- China NT PharmaのEPS 1株当たり利益 は-0.02です。
- Leyou TechnologiesのEPS 1株当たり利益 は-0.02です。
- Newmac ResourcesのEPS 1株当たり利益 は-0.02です。